New Delhi: Rajiv Gandhi Cancer Institute and Research Centre (RGCI) has completed initial clinical trials for SSI mantraIndia has its own A surgical robot. Since the launch of RGCI, RGCI Medical Director Dr. Under the guidance of Sudhir Rawal, he has been instrumental in validating the effectiveness and feasibility of this robotic system.
“RGCI is actively collaborating to develop the first Make India surgical robot which will reduce costs. Robotic surgery One third makes it more affordable and accessible”, said Dr Rawal.
After 18 procedures were carried out on SSI Mantra 1, incorporating feedback from RGCI, a refined version of surgical robot Mantra 2 was developed and after some further modifications Mantra 2 is routinely used in all complex surgeries at RGCI. RGCI has conducted 40 surgeries on Mantra 2 and an average of three surgeries are being performed every week.
Robotic surgery has revolutionized the world of minimally invasive surgery for genito-urinary tract (urology), gynecological cancers, GI cancers, and head and neck and lung cancers. The advantage of robotic surgery is the greater precision and dexterity it offers, enhanced visualization and the ability to access smaller spaces in the body.
Robotic surgery has unique advantages over traditional open surgery because the incision is much smaller, less bleeding, less pain, less incidence of wound infection. These factors translate into easier, pain-free postoperative patient recovery and earlier discharge from the hospital.
Until now, the high cost has been a barrier to the widespread use of robotics in cancer surgeries. India is very underserved when it comes to access to safe procedures offered by robotic surgeries. However, with the launch of SSI Mantra, the technology is set to become more affordable and accessible. The use of robots in mid-sized hospitals even in Tier II-III cities may soon become a reality.
